日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index

通过乳腺癌指数识别绝经前早期激素受体阳性乳腺癌患者远处复发风险最低

O'Regan, Ruth M; Ren, Yue; Zhang, Yi; Fleming, Gini F; Francis, Prudence A; Pagani, Olivia; Walley, Barbara A; Kammler, Roswitha; Dell'Orto, Patrizia; Viale, Giuseppe; Loi, Sherene; Colleoni, Marco; Treuner, Kai; Regan, Meredith M

Early-Phase Trials in Journal of Clinical Oncology

《临床肿瘤学杂志》早期试验

Stinchcombe, Thomas E; Fleming, Gini F; Craddock, Charles; Ko, Andrew H; O'Reilly, Eileen M; Maki, Robert G

Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index

乳腺癌指数对抑制卵巢功能的辅助内分泌治疗的评估

O'Regan, Ruth M; Ren, Yue; Zhang, Yi; Siuliukina, Natalia; Schnabel, Catherine A; Kammler, Roswitha; Viale, Giuseppe; Dell'Orto, Patrizia; Munzone, Elisabetta; Láng, István; Tondini, Carlo; Gomez, Henry L; Chini, Claudio; Nicoletti, Stefania Vittoria Luisa; Puglisi, Fabio; Zaman, Khalil; Goetz, Matthew P; Stearns, Vered; Martino, Silvana; Salim, Muhammad; Loibl, Sibylle; Geyer, Charles E; Bonnefoi, Hervé R; Ciruelos, Eva M; Loi, Sherene; Colleoni, Marco; Fleming, Gini F; Francis, Prudence A; Walley, Barbara A; Pagani, Olivia; Treuner, Kai; Regan, Meredith M

Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials

来自 BIG 1-98 和 SOFT 临床试验的人类表皮生长因子受体 2 低表达、激素受体阳性早期乳腺癌的基因组特征和预后意义

Luen, Stephen J; Brown, Lauren C; van Geelen, Courtney T; Savas, Peter; Kammler, Roswitha; Dell'Orto, Patrizia; Biasi, Olivia; Coates, Alan S; Gelber, Richard D; Thürlimann, Beat; Colleoni, Marco; Fleming, Gini F; Francis, Prudence A; Regan, Meredith M; Viale, Giuseppe; Loi, Sherene

A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer

一项随机II期临床试验,比较纳米白蛋白紫杉醇联合或不联合米非司酮治疗晚期三阴性乳腺癌的疗效

Chen, Nan; Matossian, Margarite; Saha, Poornima; Rampurwala, Murtuza; Kamaraju, Salaija; Hahn, Olwen; Howard, Frederick M; Fleming, Gini F; Freeman, Jincong Q; Karrison, Theodore; Conzen, Suzanne; Nanda, Rita; Stringer-Reasor, Erica M

Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer

卡铂、吉西他滨和米非司酮用于治疗晚期乳腺癌和复发/持续性上皮性卵巢癌

Stringer-Reasor, Erica M; Saha, Poornima; Kocherginsky, Masha; Lastra, Ricardo; Baker, Gabrielle; Lenygel, Ernst; Karrison, Theodore; Olalde, Lauren; Mokrzycki, Elizabeth; Hahn, Olwen M; Hoffman, Philip C; Conzen, Suzanne D; Fleming, Gini F; Nanda, Rita

Longitudinal Changes in Stress and Isolation Among Multi-Ethnic Breast Cancer Survivors Throughout COVID-19

新冠疫情期间多族裔乳腺癌幸存者压力和孤独感的纵向变化

Zhao, Fangyuan; Freeman, Jincong Q; Jaskowiak, Nora; Fleming, Gini F; Nanda, Rita; Lauderdale, Diane S; Olopade, Olufunmilayo I; Huo, Dezheng

Analysis of racial differences in HER2 status and molecular subtype in grade 3 endometroid endometrial carcinoma

对3级子宫内膜样癌中HER2状态和分子亚型的种族差异进行分析

Ackroyd, Sarah A; Sudilovsky, Gabrielle; Che, Yan; Bennett, Jennifer A; Yamada, S Diane; Fleming, Gini F

Successful treatment of gynecologic malignancy with trastuzumab deruxtecan in three patients with HER2 mutations

曲妥珠单抗德鲁替康成功治疗三例HER2突变妇科恶性肿瘤患者

Choudhury, Divya S; Kurnit, Katherine C; Yamada, S Diane; Lee, Nita K; Vemuri, Anusha; Barroeta, Julieta E; Rayani, Shayan; Straus, Christopher M; Fleming, Gini F; Kim, Josephine S

Combining Response and Toxicity Data to Implement Project Optimus

结合响应和毒性数据实施“优化项目”

Maki, Robert G; Stinchcombe, Thomas E; Schwartz, Gary K; Fleming, Gini F; Iasonos, Alexia E